Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study

Figures & data

Table 1. Patient characteristics at baseline.

	All patients (n = 20)^a
Male, n (%)	9 (45%)
Prior anti-TNF therapy, n (%)	9 (45%)
Age, years	46 [36–58]
Body weight, kg	76 [65–85]
Disease duration, years	5 [3–12]
Endoscopic Mayo score 2 (%)	14 (70%)
Endoscopic Mayo score 3 (%)	6 (30%)
Disease distribution E1 (%)	8 (40%)
Disease distribution E2 (%)	4 (20%)
Disease distribution E3 (%)	8 (40%)
Serum albumin, g/L	44 [41–45]
Serum CRP, mg/L	3.5 [1.0–13.7]
Fecal calprotectin (μg/g)	1300 [521–1800]
SCCAI	8 [5–9]
Smoking, n (%)	1 (5%)
Concomitant thiopurines	4 (20%)
Prednisolone	3 (15%)

^a Expressed as median [interquartile range] unless otherwise stated.

CRP: C-reactive protein; E1: proctitis; E2: left-sided colitis; E3: extensive colitis; n: number; TNF: tumor necrosis factor.

Figure 1. Patient flowchart. N: number of patients.

Figure 2. (a) Median [interquartile range] fecal calprotectin over time. n: number of patients. (b) Median [interquartile range] CRP over time. CRP: C-reactive protein.

Figure 3. Median [interquartile range] GLM concentrations. GLM: golimumab.

Figure 4. Week 2 and 6 median [interquartile range] GLM concentrations and area under the curve in endoscopic responders and non-responders at week 8. GLM: golimumab.